NR 566 Advanced Pharmacology - Final Exam | 140 Questions Latest 2026/2027 Update | Verified Answers
NR 566/NR566 Final Exam Qs & Ans
Advanced Pharmacology for Care of the Family - Latest 2026/2027 Update
Verified Answers - 140 Questions Comprehensive Final Examination
This comprehensive final examination covers the full scope of the NR 566 Advanced Pharmacology for Care of
the Family curriculum aligned with the 2026/2027 updated content. The 140 questions span pharmacokinetics
and pharmacodynamics, pharmacogenomics, cardiovascular, endocrine, respiratory, anti-infective,
psychopharmacology, pain management, and special populations. Each question includes detailed verified
rationales with pharmacologic mechanisms, clinical guideline references, and patient-specific considerations.
Scenario-based questions span pediatric, adult, and geriatric populations, incorporating prescriptive authority,
controlled substances, drug interactions, therapeutic drug monitoring, and deprescribing principles.
NR 566 Final Exam - Advanced Pharmacology for Care of the Family Page 1
,NR 566 Advanced Pharmacology - Final Exam | 140 Questions Latest 2026/2027 Update | Verified Answers
Section 1: Pharmacokinetics and Pharmacodynamics Across the Lifespan (Absorption,
Distribution, Metabolism, Excretion, Receptors, & Therapeutic Index)
Questions 1-14
Q1: A 72-year-old male with hepatic cirrhosis is prescribed a medication that undergoes extensive
first-pass metabolism. Which pharmacokinetic change is most expected, and what is its clinical
implication?
A. Decreased first-pass metabolism leading to higher bioavailability and reduced dose requirements [CORRECT]
B. Increased first-pass metabolism requiring higher doses
C. No change in bioavailability
D. Increased renal clearance compensating for hepatic impairment
Correct Answer: A
Rationale: Hepatic cirrhosis reduces functional hepatocyte mass and portosystemic shunting, decreasing first-pass
metabolism and increasing systemic bioavailability of orally administered drugs (e.g., propranolol, morphine, verapamil). The
clinical implication is reduced dosing requirements and risk of toxicity if standard adult dosing is used. Dose reduction and
interval extension are typically required, with careful monitoring. This is distinct from renal impairment, which affects
elimination rather than metabolism.
Q2: A 6-month-old infant receives a water-soluble medication. Compared to an adult, the infant is
expected to have:
A. Higher peak plasma concentration due to larger volume of distribution for water-soluble drugs [CORRECT]
B. Lower volume of distribution requiring higher mg/kg dosing
C. Same volume of distribution as adult
D. Increased plasma protein binding reducing free drug
Correct Answer: A
Rationale: Infants have higher total body water (70-80% vs. 60% in adults) and lower plasma protein binding (lower albumin
and alpha-1-acid glycoprotein), resulting in a larger volume of distribution for water-soluble drugs. This requires higher
weight-based dosing (mg/kg) to achieve therapeutic plasma concentrations. Conversely, lipid-soluble drugs may have a larger
Vd due to lower fat stores, but premature infants have limited fat. Plasma protein binding is reduced, increasing free drug
fraction.
Q3: A drug with a half-life of 12 hours is initiated. Approximately how many half-lives are required to reach
steady-state, and what is the corresponding time frame?
A. 3-4 half-lives; 36-48 hours
B. 5 half-lives; 60 hours [CORRECT]
C. 1 half-life; 12 hours
D. 10 half-lives; 120 hours
Correct Answer: B
Rationale: Steady-state is reached in approximately 4-5 half-lives (94-97% of steady-state). For a drug with a 12-hour half-life,
steady-state is achieved in 60 hours (5 half-lives). At this point, drug elimination equals drug administration. This principle is
essential for therapeutic drug monitoring (e.g., digoxin, lithium, anticonvulsants) where levels should be drawn at steady-state
for accurate interpretation. Loading doses can achieve therapeutic levels rapidly while steady-state accumulates.
NR 566 Final Exam - Advanced Pharmacology for Care of the Family Page 2
,NR 566 Advanced Pharmacology - Final Exam | 140 Questions Latest 2026/2027 Update | Verified Answers
Q4: A patient receives a partial agonist in the presence of a full agonist. The resulting effect is best
described as:
A. Net antagonism (reduced effect) due to competition at the receptor [CORRECT]
B. Enhanced agonist effect
C. No change in effect
D. Inverse agonism
Correct Answer: A
Rationale: A partial agonist has intrinsic activity lower than a full agonist but competes for the same receptor. In the presence
of a full agonist, the partial agonist acts as a competitive antagonist, reducing the maximal effect. Examples include
buprenorphine (partial mu-opioid agonist) displacing morphine, reducing effect; pindolol (partial beta-agonist); and aripiprazole
(partial D2 agonist). This is distinct from inverse agonism, which produces an effect opposite to the agonist by stabilizing the
inactive receptor conformation.
Q5: A medication has a narrow therapeutic index. Which monitoring parameter is most appropriate to
ensure safety and efficacy?
A. Therapeutic drug monitoring with serum drug levels [CORRECT]
B. Clinical observation only
C. Dosing based on body surface area alone
D. Pharmacogenomic testing only
Correct Answer: A
Rationale: Narrow therapeutic index drugs (e.g., warfarin, digoxin, lithium, phenytoin, vancomycin, aminoglycosides,
cyclosporine) require therapeutic drug monitoring with serum drug levels because the margin between therapeutic and toxic
doses is small. Monitoring ensures efficacy while preventing toxicity. Other monitoring parameters (e.g., INR for warfarin,
trough for vancomycin) reflect drug-specific pharmacodynamic or pharmacokinetic endpoints. Without monitoring, these drugs
carry significant risk of subtherapeutic effect or toxicity.
Q6: An 85-year-old female has reduced renal function with creatinine clearance 30 mL/min. Which
pharmacokinetic phase is most affected, and what adjustment is required?
A. Excretion; reduce dose or extend dosing interval [CORRECT]
B. Absorption; route change to IV
C. Distribution; adjust loading dose only
D. Metabolism; avoid all CYP450 substrates
Correct Answer: A
Rationale: Renal impairment primarily affects the excretion phase, prolonging elimination half-life of renally cleared drugs
(e.g., digoxin, gabapentin, allopurinol, vancomycin, many antibiotics). Dose reduction or interval extension is required to
prevent accumulation and toxicity. Loading doses (for distribution) are typically unchanged; maintenance doses must be
adjusted. Metabolism (hepatic CYP450) may be affected in severe hepatorenal syndrome but is generally preserved.
Cockcroft-Gault equation guides dosing adjustments.
NR 566 Final Exam - Advanced Pharmacology for Care of the Family Page 3
, NR 566 Advanced Pharmacology - Final Exam | 140 Questions Latest 2026/2027 Update | Verified Answers
Q7: A drug is administered orally and 70% is metabolized in the liver before reaching systemic circulation.
This phenomenon is known as:
A. First-pass effect [CORRECT]
B. Enterohepatic recirculation
C. Zero-order kinetics
D. Distribution phase
Correct Answer: A
Rationale: The first-pass effect (presystemic metabolism) refers to hepatic metabolism of orally administered drugs before
they reach systemic circulation, reducing bioavailability. Drugs with extensive first-pass effect (e.g., propranolol, morphine,
levodopa, nitroglycerin) have low oral bioavailability and may require alternative routes (sublingual, IV, transdermal) or higher
oral doses. IV administration bypasses first-pass metabolism. In liver disease, first-pass effect is reduced, increasing
bioavailability and risk of toxicity.
Q8: A drug follows zero-order elimination kinetics. Which statement best describes this process?
A. A constant amount of drug is eliminated per unit time, regardless of plasma concentration [CORRECT]
B. A constant fraction of drug is eliminated per unit time
C. Half-life remains constant
D. Doubling the dose doubles the steady-state concentration
Correct Answer: A
Rationale: In zero-order kinetics, a constant amount of drug is eliminated per unit time (e.g., 10 mg/hour) regardless of plasma
concentration. Saturation of elimination pathways (e.g., phenytoin, ethanol, high-dose aspirin, theophylline) produces this
pattern. Half-life increases with dose; steady-state concentration rises disproportionately with dose increases (small dose
increases cause large concentration increases), increasing toxicity risk. In contrast, first-order kinetics has a constant fraction
eliminated per unit time, with linear dose-concentration relationships.
Q9: An 80-year-old male receives a highly protein-bound medication (e.g., warfarin). Compared to a
younger adult, he is at increased risk of toxicity because:
A. Reduced plasma albumin increases free (active) drug fraction [CORRECT]
B. Increased albumin binds more drug
C. Reduced hepatic blood flow increases first-pass effect
D. Increased alpha-1-acid glycoprotein binds basic drugs
Correct Answer: A
Rationale: Geriatric patients and those with malnutrition, liver disease, or inflammatory states have reduced plasma albumin,
decreasing protein binding of highly bound acidic drugs (warfarin, phenytoin, valproate, sulfonamides) and increasing free
(active) drug fraction. Standard serum drug levels measure total drug (bound + free), potentially underestimating toxicity.
Clinical correlation is essential. Alpha-1-acid glycoprotein (binding basic drugs) may increase with inflammation, but this is
less clinically significant than albumin reduction in the elderly.
NR 566 Final Exam - Advanced Pharmacology for Care of the Family Page 4
NR 566/NR566 Final Exam Qs & Ans
Advanced Pharmacology for Care of the Family - Latest 2026/2027 Update
Verified Answers - 140 Questions Comprehensive Final Examination
This comprehensive final examination covers the full scope of the NR 566 Advanced Pharmacology for Care of
the Family curriculum aligned with the 2026/2027 updated content. The 140 questions span pharmacokinetics
and pharmacodynamics, pharmacogenomics, cardiovascular, endocrine, respiratory, anti-infective,
psychopharmacology, pain management, and special populations. Each question includes detailed verified
rationales with pharmacologic mechanisms, clinical guideline references, and patient-specific considerations.
Scenario-based questions span pediatric, adult, and geriatric populations, incorporating prescriptive authority,
controlled substances, drug interactions, therapeutic drug monitoring, and deprescribing principles.
NR 566 Final Exam - Advanced Pharmacology for Care of the Family Page 1
,NR 566 Advanced Pharmacology - Final Exam | 140 Questions Latest 2026/2027 Update | Verified Answers
Section 1: Pharmacokinetics and Pharmacodynamics Across the Lifespan (Absorption,
Distribution, Metabolism, Excretion, Receptors, & Therapeutic Index)
Questions 1-14
Q1: A 72-year-old male with hepatic cirrhosis is prescribed a medication that undergoes extensive
first-pass metabolism. Which pharmacokinetic change is most expected, and what is its clinical
implication?
A. Decreased first-pass metabolism leading to higher bioavailability and reduced dose requirements [CORRECT]
B. Increased first-pass metabolism requiring higher doses
C. No change in bioavailability
D. Increased renal clearance compensating for hepatic impairment
Correct Answer: A
Rationale: Hepatic cirrhosis reduces functional hepatocyte mass and portosystemic shunting, decreasing first-pass
metabolism and increasing systemic bioavailability of orally administered drugs (e.g., propranolol, morphine, verapamil). The
clinical implication is reduced dosing requirements and risk of toxicity if standard adult dosing is used. Dose reduction and
interval extension are typically required, with careful monitoring. This is distinct from renal impairment, which affects
elimination rather than metabolism.
Q2: A 6-month-old infant receives a water-soluble medication. Compared to an adult, the infant is
expected to have:
A. Higher peak plasma concentration due to larger volume of distribution for water-soluble drugs [CORRECT]
B. Lower volume of distribution requiring higher mg/kg dosing
C. Same volume of distribution as adult
D. Increased plasma protein binding reducing free drug
Correct Answer: A
Rationale: Infants have higher total body water (70-80% vs. 60% in adults) and lower plasma protein binding (lower albumin
and alpha-1-acid glycoprotein), resulting in a larger volume of distribution for water-soluble drugs. This requires higher
weight-based dosing (mg/kg) to achieve therapeutic plasma concentrations. Conversely, lipid-soluble drugs may have a larger
Vd due to lower fat stores, but premature infants have limited fat. Plasma protein binding is reduced, increasing free drug
fraction.
Q3: A drug with a half-life of 12 hours is initiated. Approximately how many half-lives are required to reach
steady-state, and what is the corresponding time frame?
A. 3-4 half-lives; 36-48 hours
B. 5 half-lives; 60 hours [CORRECT]
C. 1 half-life; 12 hours
D. 10 half-lives; 120 hours
Correct Answer: B
Rationale: Steady-state is reached in approximately 4-5 half-lives (94-97% of steady-state). For a drug with a 12-hour half-life,
steady-state is achieved in 60 hours (5 half-lives). At this point, drug elimination equals drug administration. This principle is
essential for therapeutic drug monitoring (e.g., digoxin, lithium, anticonvulsants) where levels should be drawn at steady-state
for accurate interpretation. Loading doses can achieve therapeutic levels rapidly while steady-state accumulates.
NR 566 Final Exam - Advanced Pharmacology for Care of the Family Page 2
,NR 566 Advanced Pharmacology - Final Exam | 140 Questions Latest 2026/2027 Update | Verified Answers
Q4: A patient receives a partial agonist in the presence of a full agonist. The resulting effect is best
described as:
A. Net antagonism (reduced effect) due to competition at the receptor [CORRECT]
B. Enhanced agonist effect
C. No change in effect
D. Inverse agonism
Correct Answer: A
Rationale: A partial agonist has intrinsic activity lower than a full agonist but competes for the same receptor. In the presence
of a full agonist, the partial agonist acts as a competitive antagonist, reducing the maximal effect. Examples include
buprenorphine (partial mu-opioid agonist) displacing morphine, reducing effect; pindolol (partial beta-agonist); and aripiprazole
(partial D2 agonist). This is distinct from inverse agonism, which produces an effect opposite to the agonist by stabilizing the
inactive receptor conformation.
Q5: A medication has a narrow therapeutic index. Which monitoring parameter is most appropriate to
ensure safety and efficacy?
A. Therapeutic drug monitoring with serum drug levels [CORRECT]
B. Clinical observation only
C. Dosing based on body surface area alone
D. Pharmacogenomic testing only
Correct Answer: A
Rationale: Narrow therapeutic index drugs (e.g., warfarin, digoxin, lithium, phenytoin, vancomycin, aminoglycosides,
cyclosporine) require therapeutic drug monitoring with serum drug levels because the margin between therapeutic and toxic
doses is small. Monitoring ensures efficacy while preventing toxicity. Other monitoring parameters (e.g., INR for warfarin,
trough for vancomycin) reflect drug-specific pharmacodynamic or pharmacokinetic endpoints. Without monitoring, these drugs
carry significant risk of subtherapeutic effect or toxicity.
Q6: An 85-year-old female has reduced renal function with creatinine clearance 30 mL/min. Which
pharmacokinetic phase is most affected, and what adjustment is required?
A. Excretion; reduce dose or extend dosing interval [CORRECT]
B. Absorption; route change to IV
C. Distribution; adjust loading dose only
D. Metabolism; avoid all CYP450 substrates
Correct Answer: A
Rationale: Renal impairment primarily affects the excretion phase, prolonging elimination half-life of renally cleared drugs
(e.g., digoxin, gabapentin, allopurinol, vancomycin, many antibiotics). Dose reduction or interval extension is required to
prevent accumulation and toxicity. Loading doses (for distribution) are typically unchanged; maintenance doses must be
adjusted. Metabolism (hepatic CYP450) may be affected in severe hepatorenal syndrome but is generally preserved.
Cockcroft-Gault equation guides dosing adjustments.
NR 566 Final Exam - Advanced Pharmacology for Care of the Family Page 3
, NR 566 Advanced Pharmacology - Final Exam | 140 Questions Latest 2026/2027 Update | Verified Answers
Q7: A drug is administered orally and 70% is metabolized in the liver before reaching systemic circulation.
This phenomenon is known as:
A. First-pass effect [CORRECT]
B. Enterohepatic recirculation
C. Zero-order kinetics
D. Distribution phase
Correct Answer: A
Rationale: The first-pass effect (presystemic metabolism) refers to hepatic metabolism of orally administered drugs before
they reach systemic circulation, reducing bioavailability. Drugs with extensive first-pass effect (e.g., propranolol, morphine,
levodopa, nitroglycerin) have low oral bioavailability and may require alternative routes (sublingual, IV, transdermal) or higher
oral doses. IV administration bypasses first-pass metabolism. In liver disease, first-pass effect is reduced, increasing
bioavailability and risk of toxicity.
Q8: A drug follows zero-order elimination kinetics. Which statement best describes this process?
A. A constant amount of drug is eliminated per unit time, regardless of plasma concentration [CORRECT]
B. A constant fraction of drug is eliminated per unit time
C. Half-life remains constant
D. Doubling the dose doubles the steady-state concentration
Correct Answer: A
Rationale: In zero-order kinetics, a constant amount of drug is eliminated per unit time (e.g., 10 mg/hour) regardless of plasma
concentration. Saturation of elimination pathways (e.g., phenytoin, ethanol, high-dose aspirin, theophylline) produces this
pattern. Half-life increases with dose; steady-state concentration rises disproportionately with dose increases (small dose
increases cause large concentration increases), increasing toxicity risk. In contrast, first-order kinetics has a constant fraction
eliminated per unit time, with linear dose-concentration relationships.
Q9: An 80-year-old male receives a highly protein-bound medication (e.g., warfarin). Compared to a
younger adult, he is at increased risk of toxicity because:
A. Reduced plasma albumin increases free (active) drug fraction [CORRECT]
B. Increased albumin binds more drug
C. Reduced hepatic blood flow increases first-pass effect
D. Increased alpha-1-acid glycoprotein binds basic drugs
Correct Answer: A
Rationale: Geriatric patients and those with malnutrition, liver disease, or inflammatory states have reduced plasma albumin,
decreasing protein binding of highly bound acidic drugs (warfarin, phenytoin, valproate, sulfonamides) and increasing free
(active) drug fraction. Standard serum drug levels measure total drug (bound + free), potentially underestimating toxicity.
Clinical correlation is essential. Alpha-1-acid glycoprotein (binding basic drugs) may increase with inflammation, but this is
less clinically significant than albumin reduction in the elderly.
NR 566 Final Exam - Advanced Pharmacology for Care of the Family Page 4
